Pharma
AstraZeneca’s Tezepelumab (thymic stromal lymphopoietin antagonist) Receives FDA BT Designation
Shots: The designation is based on P-IIb PATHWAY assessing (tezepelumab vs PBO) in patients with asthma exacerbations, uncontrolled asthma receiving inhaled corticosteroids/LA- β2-agonists w/o oral corticosteroids and additional asthma controllers […]readmore